Insmed ( (INSM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Insmed’s stock has faced downward pressure despite positive developments around its drug pipeline, specifically the potential of brensocatib in treating chronic rhinosinusitis without nasal polyps. Analysts remain optimistic about upcoming Phase 2 BiRCh trial results and have raised price targets based on improved revenue forecasts and increased probabilities of success. However, negative insider sentiment, highlighted by recent insider selling activities, appears to have weighed on the stock.
More about Insmed
YTD Price Performance: 186.88%
Average Trading Volume: 2,446,954
Technical Sentiment Signal: Buy
Current Market Cap: $42.8B
For further insights into INSM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.